Nitric oxide signaling in the ischemic postconditioning of human heart muscle (RCD code: III)

Marcin Kunecki, Wojciech Płazak, Piotr Podolec, Tomasz Roleder, Jolanta Biernat, Piotr Kogut, Marek A Deja, Krzysztof S Gołba

Full Text:

PDF

Abstract


Background: Ischemic heart conditioning is well documented to trigger the intrinsic protective mechanisms of resistance against ischemia/reperfusion (I/R) injury. Previous studies on animal model have suggested that the nitric oxide (NO) mediates the beneficial effect of ischemic postconditioning (POC). We tested the hypothesis that POC provide cardioprotection in the NO-dependent mechanism in the human myocardium.

Methods: Human atrial trabeculae were subjected to simulated I/R injury. To achieve POC triple brief hypoxia periods were followed by the lethal hypoxia. Non-selective inhibitor of NO synthase: NG-monomethyl-L-arginine (L-NMMA) was used at the time of re-oxygenation in the POC protocol. Contractility of the myocardium was assessed as the maximal force of a contraction (Amax), the rate of rise of the force of a contraction (Slope L) and cardiac muscle relaxation – as the rate of decay of the force of a contraction (Slope T).

Results:  Co-application of L-NMMA with POC resulted in the decrease of Amax, Slope L and Slope T during re-oxygenation period as compared to POC only.

Conclusions:  At re-oxygenation period, the blockade of NO synthesis has deleterious effect on systolic and diastolic function of human myocardium, as well as attenuates the beneficial effect of ischemic.


Keywords


ischemic heart disease; reperfusion; cardioprotection; nitric oxide synthase

References


Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: new strategies for cardioprotection. Diabetes Obes Metab 2008;10:451–459.

Ghosh S, Standen NB, Galinanes M. Preconditioning the human myocardium by simulated ischemia: studies on the early and delayed protection. Cardiovasc Res 2000; 45: 339–350.

Sivaraman V, Mudalagiri NR, Di Salvo C et al. Postconditioning protects human atrial muscle through the activation of the RISK pathway. Basic Res Cardiol 2007; 102: 453–459.

Yellon DM, Alkhulaifi AM, Pugsley WB. Preconditioning the human myocardium. Lancet 1993; 342: 276–277.

Alkhulaifi AM, Yellon DM, Pugsley WB. Preconditioning the human heart during aorto-coronary bypass surgery. Eur J Cardiothorac Surg 1994; 8: 270–275.

Staat P, Rioufol G, Piot C et al. Postconditioning the human heart. Circulation 2005; 112: 2143–2148.

Luo W, Li B, Chen R, et al. Effect of ischemic postconditioning in adult valve replacement. Eur J Cardiothorac Surg 2008; 33: 203–208.

Halkos ME, Kerendi F, Corvera JS et al. Myocardial protection with postconditioning is not enhanced by ischemic preconditioning. Ann Thorac Surg 2004; 78: 961–969.

Zhao ZQ, Corvera JS, Halkos M,et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003; 285: H579-H588.

Lochner A, Marais E, Genade S, et al. Nitric oxide: A trigger for classic preconditioning? Am J Physiol Heart Circ Physiol 2000; 279: H2752–H2765.

Penna C, Cappello S, Mancardi D et al. Post-conditioning reduces infarct size in the isolated rat heart: Role of coronary flow and pressure and the nitric oxide/cGMP pathway. Basic Res Cardiol 2006; 101: 168–179.

Trochu JN, Bouhour JB, Kaley G, et al. Role of endothelium-derived nitric oxide in the regulation of cardiac oxygen metabolism: implications in health and disease. Circ Res 2000;87: 1108–1117.

Zalewski J, Nessler J. The endogenous cardioprotection during reperfusion in acute myocardial infarction. Kardiol Pol. 2011; 69 Suppl 3: 67–74.

Headrick JP, See Hoe LE, Du Toit EF, et al. Opioid receptors and cardioprotection –‘opioidergic conditioning’ of the heart. Brit J Pharm 2015; 172 2026–2050.

Correa F, Buelna-Chontal M, Chagoya V, et al. Inhibition of the nitric oxide/ cyclic guanosine monophosphate pathway limited the cardioprotective effect of post- conditioning in hearts with apical myocardial infarction. Eur J Pharmacol 2015; 765: 472–481.

Folino A, Losano G, Rastaldo. Balance of Nitric Oxide and Reactive Oxygen Species in Myocardial Reperfusion Injury and Protection. J Cardiovasc Pharmacol 2013; 62: 567–575.

Roleder T, Gołba KS, Kunecki M,et al. The co-application of hypoxic preconditioning and postconditioning abolishes their own protective effect on systolic function in human myocardium. Cardiol J 2013, 20: 472–477.

Tsang A, Hausenloy DJ, Mocanu MM, et al. Postconditioning: a form of “modified reperfusion” protects the myocardium by activating the phosphatidylinositol 3-kinase- Akt pathway. Circ Res 2004; 95: 230–232.

Yang X, Downey JM, Cohen MV. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by activation of ERK and production of nitric oxide. Circulation. 2003; 108 (suppl IV): 158.




DOI: http://dx.doi.org/10.20418%2Fjrcd.vol2no6.228

Refbacks

  • There are currently no refbacks.
Journal of Rare Cardiovascular Diseases (JRCD)
John Paul II Hospital in Kraków, 80 Prądnicka Str., 31-202 Kraków, Poland
Phone: +48 (12) 614 33 99, +48 (12) 614 34 88 Fax: +48 (12) 614 34 88
e-mail: rarediseases@szpitaljp2.krakow.pl
Published by SoftQ sp. z o.o.
ul. Oleandry 2, 30-063 Kraków, Poland
Phone: +48 (12) 444 1650 Fax: +48 (12) 444 1659
e-mail: softq@softq.pl